Nimbus Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Nimbus Therapeutics, Inc.
Private Company Edition: Acelyrin will use its latest funding for Phase III development of izokibep in inflammatory diseases. Also, ArsenalBio raised $220m to take its programmable cell therapies into the clinic and RayzeBio’s $160m series D round will fund clinical trials for its radiopharmaceuticals.
Emerging Company Profile: The French firm, which is developing the lead CTP synthase 1 inhibitor in the pipeline, plans to address a range of cancers with its highly selective approach.
Glenmark is set to initiate a Phase I study for its inhibitor of immuno-oncology target hematopoietic progenitor kinase 1 (HPK1), a segment that has seen increased activity over the recent past with BeiGene, Nimbus and Treadwell Therapeutics among those advancing their molecules.
Seattle biotech raised $36m series A in March, now obtains glaucoma and AMD drug candidates along with delivery technology. Alligator, Orion partner on bispecific antibodies for cancer.
- Drug Discovery Tools
Drug Discovery Tools
- Other Names / Subsidiaries
- Nimbus Discovery LLC